![Placeholder Image Placeholder Image](https://www.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
-
Media ReleaseNovartis resumes production and delivery of radioligand therapy medicines ahead of schedule
-
Media ReleaseNew Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
-
Media ReleaseNovartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer
-
Media ReleaseNovartis presents new data in breast and prostate cancer at ESMO
-
Media ReleaseNovartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis announces tislelizumab demonstrated efficacy and tolerability in first-line advanced liver cancer in Phase III trial
-
Media ReleaseNovartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer
-
Media ReleaseNovartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
-
Media ReleaseNovartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
-
Media ReleaseNovartis receives European Commission approval for Tabrecta® for the treatment of METex14 skipping advanced non-small cell lung cancer
-
Media ReleaseNovartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 10
- › Next page